Literature DB >> 26467322

Renal Dysfunction, CHADS2 Score, and Adherence to the Anticoagulant Treatment in Nonvalvular Atrial Fibrillation.

Yihong Sun1, Yitong Wang1, Juan Jiang1, Lina Wang1, Dayi Hu1.   

Abstract

We investigated the risk of stroke associated with renal dysfunction and the impact of warfarin therapies in Chinese patients with nonvalvular atrial fibrillation (NVAF). Information was collected on age, sex, height, weight, type of atrial fibrillation, and serum creatinine within the previous 6 months, together with the variables needed to calculate the CHADS2 score. For patients not taking warfarin, reasons why not were recorded. Three thousand seventeen eligible patients with NVAF, mean (1 standard deviation [SD]) age of 67.7 (13.0) years, from 50 Chinese hospitals were included from May 2012 to October 2012, with a mean (1SD) CHADS2 score of 2.0 (1.5). Of these, 58.3% were male and 86.2% were at high risk of stroke with a CHADS2 score ≥1. Only 42.6% were on warfarin, and 22.5% of the patients had moderate or severe renal impairment (estimated glomerular filtration rate < 60 mL/min/1.73 m2). After adjustment for the CHADS2 score, renal dysfunction remained moderately but significantly associated with the risk of stroke/TIA (odds ratio = 1.005, 95% confidence interval: 1.002-1.009, P = .002). There was, however, no significant difference in anticoagulant usage between patients with or without impaired renal dysfunction. The most common anticoagulant concerns were the low proportion of patients with regular international normalized ratio monitoring (43.0%) and the risk of bleeding (33.3%). Renal impairment was common and independently associated with the risk of cerebrovascular embolism in Chinese patients with NVAF but not independently related to underuse of anticoagulant treatment.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; renal function

Mesh:

Substances:

Year:  2016        PMID: 26467322     DOI: 10.1177/1076029615611250

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  4 in total

1.  Author`s Reply.

Authors:  Anca Ouatu; Mariana Floria; Catalina Arsenescu Georgescu
Journal:  Anatol J Cardiol       Date:  2016-01       Impact factor: 1.596

2.  Rationale and design of the improving Care for Cardiovascular Disease in China (CCC) project: a national registry to improve management of atrial fibrillation.

Authors:  Yongchen Hao; Jing Liu; Sidney C Smith; Yong Huo; Gregg C Fonarow; Junbo Ge; Jun Liu; Kathryn A Taubert; Louise Morgan; Yang Guo; Mengge Zhou; Dong Zhao; Changsheng Ma
Journal:  BMJ Open       Date:  2018-07-05       Impact factor: 2.692

3.  Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study.

Authors:  Ni Suo; Yan-Min Yang; Juan Wang; Han Zhang; Xing-Hui Shao; Shuang Wu; Jun Zhu
Journal:  Front Cardiovasc Med       Date:  2022-03-18

4.  Prevalence, awareness, treatment, and control rates of hypertension in patients hospitalized with atrial fibrillation in China: Findings from the CCC-AF project.

Authors:  Zhaoqing Sun; Yongchen Hao; Jun Liu; Na Yang; Yue Qi; Danqing Hu; Yiqian Yang; Haimei Wang; Dong Zhao; Caihua Sang; Jing Liu
Journal:  Front Cardiovasc Med       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.